REHOVOT, Israel and JERSEY CITY, New Jersey, November 5
/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in
the development of microRNA-based diagnostics, announced today it will
present at the Rodman & Renshaw 10th Annual Healthcare Conference on
Wednesday, November 10 at The New York Palace Hotel in New York City.
About MicroRNA
MicroRNAs (miRNAs) are recently discovered, naturally occurring, small
RNAs that act as master regulators and have the potential to form the basis
for a new class of diagnostics and therapeutics. Since many diseases are
caused by the abnormal activity of proteins, the ability to selectively
regulate protein activity through microRNAs could provide the means to treat
a wide range of human diseases. In addition, microRNAs have been shown to
have different expression in various pathological conditions. As a result,
these differences may provide for a novel diagnostic strategy for many
diseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.
Founded in 2000, the company's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to the
discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong IP position and proprietary platform technologies,
Rosetta Genomics is working on the application of these technologies in the
development of a full range of microRNA-based diagnostic and therapeutic
tools, focusing primarily on cancer and various women's health indications.
The company expects that the first microRNA diagnostic tests applying its
technology will be launched by licensed clinical laboratories in the United
States in 2008.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future
expectations, plans and prospects, including without limitation, statements
relating to the role of microRNAs in human physiology and disease, the
potential of microRNAs in the diagnosis and treatment of disease and the
expected timing of submission for approval and launch of diagnostic tests
using our microRNA technology constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by these forward-looking statements as a result of various
important factors, including risks related to: Rosetta's approach to discover
microRNA technology and to work on the application of this technology in the
development of novel diagnostics and therapeutic tools, which is unproven and
may never lead to marketable products or services; Rosetta's ability to fund
and the results of further pre-clinical and clinical trials; Rosetta's
ability to obtain, maintain and protect the intellectual property utilized by
Rosetta's products; Rosetta's ability to enforce its patents against
infringers and to defend its patent portfolio against challenges from third
parties; Rosetta's ability to obtain additional funding to support its
business activities; Rosetta's dependence on third parties for development,
manufacture, marketing, sales, and distribution of products; Rosetta's
ability to successfully develop its candidate tools, products and services,
all of which are in early stages of development; Rosetta's ability to obtain
regulatory clearances or approvals that may be required for its products and
services; the ability to obtain coverage and adequate payment from health
insurers for the products and services comprising Rosetta's technology;
competition from others using technology similar to Rosetta's and others
developing products for similar uses; Rosetta's dependence on collaborators;
and Rosetta's short operating history; as well as those risks more fully
discussed in the "Risk Factors" section of Rosetta's Annual Report on Form
20-F for the year ended December 31, 2007 as filed with the Securities and
Exchange Commission. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be relied
upon as representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless
required by law.
Media & Investors
Ron Kamienchick
T: +972-73-222-0730
E: media@rosettagenomics.com
SOURCE Rosetta Genomics Ltd
